Arcturus Therapeutics Shares Jump 23% on Positive Observations for Potential Cystic Fibrosis Treatment

Dow Jones05-28

By Sabela Ojea

Shares of Arcturus Therapeutics on Tuesday jumped after the company said it saw positive observations in the phase 1 study for its cystic fibrosis treatment candidate ARCT-032.

The stock was up 23% to $37.40 in recent trading. Shares have risen 37% over the past 12 months.

The late-stage clinical messenger RNA medicines and vaccines company said that the treatments for the first four patients were generally safe and well tolerated, without serious adverse events.

"Furthermore, we observed an encouraging trend towards lung function improvements in the first four cystic fibrosis participants after only two inhaled administrations," Chief Executive Joseph Payne said.

Arcturus will present this new Phase 1b interim data at the June 7 European cystic fibrosis conference in Scotland.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

May 28, 2024 11:55 ET (15:55 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2438304955?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-28 23:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2438304955","market":"sg","top_or_hot":-1,"title":"Arcturus Therapeutics Shares Jump 23% on Positive Observations for Potential Cystic Fibrosis Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Arcturus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> on Tuesday jumped after the company said it saw positive observations in the phase 1 study for its cystic fibrosis treatment candidate ARCT-032. \n</p>\n<p>\n  The stock was up 23% to $37.40 in recent trading. Shares have risen 37% over the past 12 months. \n</p>\n<p>\n  The late-stage clinical messenger RNA medicines and vaccines company said that the treatments for the first four patients were generally safe and well tolerated, without serious adverse events. \n</p>\n<p>\n   \"Furthermore, we observed an encouraging trend towards lung function improvements in the first four cystic fibrosis participants after only two inhaled administrations,\" Chief Executive Joseph Payne said. \n</p>\n<p>\n  Arcturus will present this new Phase 1b interim data at the June 7 European cystic fibrosis conference in Scotland. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 28, 2024 11:55 ET (15:55 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arcturus Therapeutics Shares Jump 23% on Positive Observations for Potential Cystic Fibrosis Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcturus Therapeutics Shares Jump 23% on Positive Observations for Potential Cystic Fibrosis Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-28 23:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Sabela Ojea \n\n\n \n\n\n  Shares of Arcturus Therapeutics on Tuesday jumped after the company said it saw positive observations in the phase 1 study for its cystic fibrosis treatment candidate ARCT-032....</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARCT","symbol_name":"Arcturus Therapeutics Ltd.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2438304955","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2438304955","pubTimestamp":1716911700,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Arcturus Therapeutics on Tuesday jumped after the company said it saw positive observations in the phase 1 study for its cystic fibrosis treatment candidate ARCT-032.The stock was up 23% to $37.40 in recent trading. Shares have risen 37% over the past 12 months.The late-stage clinical messenger RNA medicines and vaccines company said that the treatments for the first four patients were generally safe and well tolerated, without serious adverse events.\"Furthermore, we observed an encouraging trend towards lung function improvements in the first four cystic fibrosis participants after only two inhaled administrations,\" Chief Executive Joseph Payne said.Arcturus will present this new Phase 1b interim data at the June 7 European cystic fibrosis conference in Scotland.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARCT":"Arcturus Therapeutics Ltd.","LENZ":"Therapeutics","BK4139":"生物科技"},"translate_title":"Arcturus Therapeutics股价因潜在囊性纤维化治疗的积极观察而上涨23%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"ARCT":0.9},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Shares of Arcturus Therapeutics on Tuesday jumped after the company said it saw positive observations in the phase 1 study for its cystic fibrosis treatment candidate ARCT-032. \n\n\n  The stock was up 23% to $37.40 in recent trading. Shares have risen 37% over the past 12 months. \n\n\n  The late-stage clinical messenger RNA medicines and vaccines company said that the treatments for the first four patients were generally safe and well tolerated, without serious adverse events. \n\n\n   \"Furthermore, we observed an encouraging trend towards lung function improvements in the first four cystic fibrosis participants after only two inhaled administrations,\" Chief Executive Joseph Payne said. \n\n\n  Arcturus will present this new Phase 1b interim data at the June 7 European cystic fibrosis conference in Scotland. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 28, 2024 11:55 ET (15:55 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2438304955"}